These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 34214475)

  • 1. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
    Nathan SD; Waxman A; Rajagopal S; Case A; Johri S; DuBrock H; De La Zerda DJ; Sahay S; King C; Melendres-Groves L; Smith P; Shen E; Edwards LD; Nelsen A; Tapson VF
    Lancet Respir Med; 2021 Nov; 9(11):1266-1274. PubMed ID: 34214475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.
    Waxman A; Restrepo-Jaramillo R; Thenappan T; Ravichandran A; Engel P; Bajwa A; Allen R; Feldman J; Argula R; Smith P; Rollins K; Deng C; Peterson L; Bell H; Tapson V; Nathan SD
    N Engl J Med; 2021 Jan; 384(4):325-334. PubMed ID: 33440084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial.
    Nathan SD; Tapson VF; Elwing J; Rischard F; Mehta J; Shapiro S; Shen E; Deng C; Smith P; Waxman A
    Am J Respir Crit Care Med; 2022 Jan; 205(2):198-207. PubMed ID: 34767495
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.
    Waxman A; Restrepo-Jaramillo R; Thenappan T; Engel P; Bajwa A; Ravichandran A; Feldman J; Hajari Case A; Argula RG; Tapson V; Smith P; Deng C; Shen E; Nathan SD
    Eur Respir J; 2023 Jun; 61(6):. PubMed ID: 37080567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.
    Sadushi-Kolici R; Jansa P; Kopec G; Torbicki A; Skoro-Sajer N; Campean IA; Halank M; Simkova I; Karlocai K; Steringer-Mascherbauer R; Samarzija M; Salobir B; Klepetko W; Lindner J; Lang IM
    Lancet Respir Med; 2019 Mar; 7(3):239-248. PubMed ID: 30477763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes.
    Nathan SD; Deng C; King CS; DuBrock HM; Elwing J; Rajagopal S; Rischard F; Sahay S; Broderick M; Shen E; Smith P; Tapson VF; Waxman AB
    Chest; 2023 Feb; 163(2):398-406. PubMed ID: 36115497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
    Maher TM; Tudor VA; Saunders P; Gibbons MA; Fletcher SV; Denton CP; Hoyles RK; Parfrey H; Renzoni EA; Kokosi M; Wells AU; Ashby D; Szigeti M; Molyneaux PL;
    Lancet Respir Med; 2023 Jan; 11(1):45-54. PubMed ID: 36375479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
    JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD.
    Kolb M; Orfanos SE; Lambers C; Flaherty K; Masters A; Lancaster L; Silverstein A; Nathan SD
    Adv Ther; 2022 Sep; 39(9):3881-3895. PubMed ID: 35781186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study.
    Weatherald J; Nathan SD; El-Kersh K; Argula RG; DuBrock HM; Rischard FP; Cassady SJ; Tarver J; Levine DJ; Tapson VF; Deng C; Shen E; Das M; Waxman AB
    BMJ Open Respir Res; 2024 Mar; 11(1):. PubMed ID: 38519114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis.
    Nathan SD; Behr J; Cottin V; Lancaster L; Smith P; Deng CQ; Pearce N; Bell H; Peterson L; Flaherty KR
    BMJ Open Respir Res; 2022 Jul; 9(1):. PubMed ID: 35787522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study.
    Ismat FA; Usansky HH; Villa R; Zou J; Teper A
    Adv Ther; 2022 Nov; 39(11):5144-5157. PubMed ID: 36070132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.
    Nathan SD; Behr J; Collard HR; Cottin V; Hoeper MM; Martinez FJ; Corte TJ; Keogh AM; Leuchte H; Mogulkoc N; Ulrich S; Wuyts WA; Yao Z; Boateng F; Wells AU
    Lancet Respir Med; 2019 Sep; 7(9):780-790. PubMed ID: 31416769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.